Oncology

The European Medicines Agency will begin a centralized review process for subcutaneous nivolumab across multiple solid tumor indications.

Patients 12 years and older with NTRK gene fusion-positive solid tumors may now receive repotrectinib.

Public health researchers highlight how they learned to overcome and adapt to disparities observed during their careers.

Neil M. Iyengar, MD, focuses on the use of artificial intelligence in the oncology space.

Health economists discuss their interests in the outcomes observed from the Affordable Care Act and its impact on specific populations.

Cathy Bradley, PhD, and Lindsay M. Sabik, PhD, spoke about moving the needle forward in the public health space through research and persistence.

An AI-based system may reduce the time needed to match patients with cancer to suitable clinical trials.

Data support revisiting goals of care conversations with patients with very advanced cancer who have significantly progressed with their disease.

Rates of HPV-related cancers may be decreased in patients under 40 have received an HPV vaccine.

Ted A. James, MD, MHCM, FACS, spoke about integrating artificial intelligence into oncology care.

Patients with cancer who underwent surgery during the COVID-19 pandemic were also more likely to have respiratory complications.

While treatment centered around multiple drug options is common practice in oncology, the use of complementary and medicine alternative medicine is being introduced in the space.

Data from the CheckMate-67T trial support the biologics license application for subcutaneous nivolumab in multiple solid tumors.

Findings from a health disparities report may support new policies designed to narrow persistent racial and ethnic disparities in health outcomes.

Additional research may be necessary to validate the efficacy of telehealth interventions in clinical activities for patients with cancer.

Lack of energy, difficulty with sleeping, and pain were some of the most common symptoms reported in older patients with cancer.

“If you were to ask me what the 1 magic thing would be, it would be that we would adopt a concept of 1 team, one fight nationally, and that we would be able to have our structures and our coordination of care.”

Patients with advanced solid tumors may be able to stay on treatment with saruparib longer compared with other approved PARP inhibitors, thereby improving efficacy.

Results from 3 DESTINY trials led to the accelerated approval of fam-trastuzumab deruxtecan-nxki for patients with unresectable or metastatic HER2-positive solid tumors.

Further research may be needed to help determine the underlying mechanisms of polybrominated diphenyl ether exposure contributing to the risk of cancer-related mortality.

If possible, targeting the BER pathway for drug sensitivities may increase therapeutic options for managing solid cancers, wrote Channing Paller, MD.

An updated guideline from ASCO highlights appropriate use of vaccines for patients with cancer receiving treatments such as CAR T-cell therapy or B-cell depleting therapy.

Investigators will evaluate the preliminary efficacy and safety of NST-628 in adult patients with solid tumors harboring mutations in the RAS-MAPK pathway as part of a phase 1 trial.

Cancer vaccines are a “cross-cutting approach” that may be applicable across several cancer types, according to Catherine J. Wu, MD.

mRNA may be a potential modality for developing cancer-based vaccines, according to Catherine J. Wu, MD.

Analyzing the KRAS mutation across various cancer types may be a worthwhile target when using a cancer vaccine or immunotherapy, says Catherine J. Wu, MD.

Edward S. Kim, MD, MBA, and Richard T. Lee, MD discuss how integrative oncology techniques such as acupuncture have impacted patient quality of life at their practice.

Primary care physicians cannot afford to dismiss younger people who present with symptoms of cancer in the face of increasing cancer incidence, according to Monique Gary, DO, MSc, FACS.

In a recent Hot Topics article, reimbursement rates for Medicare physicians are discussed, and how it will impact their practice.

Denosumab biosimilars have been approved by the FDA as Wyost and Jubbonti across various reference indications.